HC Wainwright Issues Negative Outlook for EYPT Earnings

Key Points

• HC Wainwright lowered its EPS estimates for EyePoint Pharmaceuticals, forecasting a Q3 2026 loss of $0.60 per share versus its prior estimate of $0.48 and a FY2026 loss of $3.15 per share. Despite the revisions, it maintained a Buy rating and $27 price target.
• EyePoint’s latest quarter showed a wider-than-expected loss of $1.09 per share, compared with the $1.01 consensus estimate, although revenue of $0.51 million exceeded expectations.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $44.38, but the company continues to face substantial operating losses and profitability risks.

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Research analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for Eyepoint Pharmaceuticals in a report issued on Thursday, August 6th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.60) per share for the quarter, down from their prior forecast of ($0.48). HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Eyepoint Pharmaceuticals' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals' Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($3.15) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.84) EPS.

Other equities research analysts have also issued reports about the stock. Chardan Capital restated a "buy" rating and set a $65.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Friday. Stifel Nicolaus initiated coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a "buy" rating and a $40.00 price target for the company. Cantor Fitzgerald raised their price objective on shares of Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the company an "overweight" rating in a research note on Thursday. Royal Bank Of Canada decreased their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Finally, Guggenheim restated a "buy" rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eyepoint Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $44.38.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $13.89 on Monday. Eyepoint Pharmaceuticals has a fifty-two week low of $9.65 and a fifty-two week high of $19.11. The firm's 50-day simple moving average is $13.11 and its 200-day simple moving average is $13.77. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -3.71 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million during the quarter, compared to analysts' expectations of $0.45 million.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its stake in Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company's stock valued at $85,000 after acquiring an additional 794 shares during the period. RWC Asset Management LLP increased its holdings in shares of Eyepoint Pharmaceuticals by 6.4% in the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company's stock worth $315,000 after acquiring an additional 1,040 shares in the last quarter. MCF Advisors LLC raised its position in shares of Eyepoint Pharmaceuticals by 8.3% during the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company's stock worth $273,000 after purchasing an additional 1,149 shares during the period. Raymond James Financial Inc. raised its position in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock worth $112,000 after purchasing an additional 1,177 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company's stock valued at $74,000 after purchasing an additional 1,358 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: RBC Capital maintained its Buy rating on EyePoint Pharmaceuticals, supporting the bullish view of the company’s long-term prospects. RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals
• Positive Sentiment: One analyst price target was raised to $55, implying substantial upside from the stock’s recent trading level and reinforcing expectations that EyePoint’s development pipeline could create significant value. Eyepoint Pharmaceuticals Price Target Raised to $55.00
• Positive Sentiment: A review of EyePoint’s Phase 3 trial design argued that its approach could strengthen the durability profile of its lead programs. Longer-lasting treatments could improve commercial differentiation and the potential market opportunity if clinical results are successful. EyePoint Phase 3 Design Creates a More Valuable Durability Story
• Neutral Sentiment: HC Wainwright retained its Buy rating but kept a $27 price target, indicating continued confidence in EyePoint’s long-term potential despite near-term financial pressure.
• Negative Sentiment: HC Wainwright lowered its price target to $27 from a higher prior level and reduced EPS forecasts across 2026 and 2027. Its FY2026 loss estimate moved to $3.15 per share from $2.69, while FY2027 loss expectations widened to $1.84 from $1.74. The revisions point to higher anticipated expenses or slower progress toward profitability. HC Wainwright Cuts EyePoint Pharmaceuticals Price Target
• Negative Sentiment: The company’s latest quarterly results also showed ongoing losses: EyePoint reported a $1.09 per-share loss, wider than the $1.01 consensus estimate, although revenue slightly exceeded expectations. Continued cash use and substantial operating losses remain key risks for investors.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source